` REGN (Regeneron Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

REGN
vs
S&P 500

Over the past 12 months, REGN has underperformed S&P 500, delivering a return of -40% compared to the S&P 500's 12% growth.

Stocks Performance
REGN vs S&P 500

Loading

Performance Gap
REGN vs S&P 500

Loading
REGN
S&P 500
Difference

Performance By Year
REGN vs S&P 500

Loading
REGN
S&P 500
Add Stock

Competitors Performance
Regeneron Pharmaceuticals Inc vs Peers

S&P 500
REGN
ABBV
AMGN
GILD
VRTX
Add Stock

Regeneron Pharmaceuticals Inc
Glance View

Economic Moat
Narrow
Market Cap
64.3B USD
Industry
Biotechnology

In the vibrant world of biotechnology, Regeneron Pharmaceuticals Inc. emerged as a powerhouse by meticulously weaving together science and medicine. Founded in 1988 by a visionary team, including celebrated scientists Dr. Leonard Schleifer and Dr. George Yancopoulos, Regeneron was created with an ambitious mission to harness the power of biology to bring innovative medicines to patients. The company began its journey with a strong emphasis on research and development, evolving its unique approach to drug discovery focused on the rapid and precise identification of biologically relevant targets. With a strategic location at the heart of New York's biotechnology valley, Regeneron thrived, investing substantially in proprietary technologies and developing a robust pipeline of therapeutics aimed at addressing critical unmet medical needs across various domains such as ophthalmology, immunology, oncology, and rare diseases. Today, Regeneron makes its mark in the pharmaceutical industry primarily through its innovative product portfolio, comprised of renowned drugs like EYLEA, a leading treatment for retinal diseases, and Dupixent, a medication for atopic dermatitis and other allergic conditions. The company's revenue model relies heavily on the commercial success of these drugs, supported by strategic collaborations and partnerships with industry giants like Sanofi. Their success is driven by a commitment to leveraging cutting-edge technology platforms, such as the VelociSuite, which expedites drug discovery and development processes. Regeneron’s emphasis on precision and quality, coupled with an agile business model that adapts to health landscapes, allows it to maintain a competitive edge in a rapidly evolving industry while consistently delivering robust financial performance.

REGN Intrinsic Value
664.94 USD
Undervaluation 11%
Intrinsic Value
Price
Back to Top